Collectively, these results demonstrate that EDN1 overexpression drives oxaliplatin resistance in CRC, while its depletion restores chemosensitivity, underscoring its pivotal role in oxaliplatin resistance. The gene discussed is EDN1; the disease is colorectal carcinoma.